专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明公开

EP2364721A1 Vaccine compositions comprising a saponin adjuvant 无效
标题翻译：含皂苷佐剂的疫苗组合物
公开(公告)号：EP2364721A1
公开(公告)日：2011-09-14
申请号：EP11168821.4
申请日：2006-12-12
申请人： GlaxoSmithKline Biologicals S.A.
发明人： Vandepapeliere, Pierre
IPC分类号： A61K39/00 , A61K39/12 , A61K39/145
CPC分类号： A61K39/39 , A61K39/00 , A61K39/015 , A61K39/092 , A61K39/102 , A61K39/1045 , A61K39/12 , A61K39/145 , A61K2039/5258 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/55555 , A61K2039/55572 , A61K2039/55577 , A61K2039/57 , A61K2039/6037 , A61K2039/6068 , A61K2039/70 , C12N2710/16134 , C12N2710/16171 , C12N2710/16734 , C12N2710/16771 , C12N2710/20071 , C12N2730/10134 , C12N2760/16134 , C12N2760/16171 , C12N2760/16234 , C12N2760/16271 , C12N2760/20034 , Y02A50/412
摘要： The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30µg. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 µg of a lipopolysaccharide and between 1 and 30 µg of an immunologically active saponin fraction presented in the form of a liposome.

32. 发明公开

EP2363463A1 Novel baculoviral vector 有权
标题翻译：新型杆状病毒载体
公开(公告)号：EP2363463A1
公开(公告)日：2011-09-07
申请号：EP10193968.4
申请日：2007-02-08
申请人： Educational Foundation Jichi Medical University , OTSUKA PHARMACEUTICAL CO., LTD.
发明人： Yoshida, Shigeto , Ohba, Yoshio , Hariguchi, Norimitsu , Mizukoshi, Masami , Kawasaki, Masanori , Matsumoto, Makoto , Goto, Yoshihiro
IPC分类号： C12N15/00 , A61K35/76 , A61K39/12 , A61P31/12 , C12N7/00 , C12N15/09
CPC分类号： C12N15/86 , A61K39/00 , A61K39/015 , A61K39/04 , A61K39/12 , A61K39/145 , A61K2039/525 , A61K2039/5256 , A61K2039/543 , A61K2039/544 , C07K14/005 , C07K2319/02 , C07K2319/43 , C12N2710/14143 , C12N2760/16134 , C12N2830/205 , Y02A50/386 , Y02A50/394 , Y02A50/41 , Y02A50/412
摘要： A recombinant transfer vector capable of expressing a foreign gene fused to a viral gene under the control of a dual promoter and a recombinant baculovirus, and methods for production thereof, as well as pharmaceuticals comprising the recombinant baculovirus as an active ingredient.
摘要翻译：本发明提供一种能够在双重启动子和重组杆状病毒的控制下表达与病毒基因融合的外源基因的重组转移载体及其制备方法，以及包含该重组杆状病毒作为有效成分的药物。

33. 发明授权

EP1802336B1 MALARIA PRIME/BOOST VACCINES 有权
标题翻译：初免 - 加强疫苗恶性疟原虫
公开(公告)号：EP1802336B1
公开(公告)日：2011-09-07
申请号：EP05808091.2
申请日：2005-10-13
申请人： Crucell Holland B.V. , GlaxoSmithKline Biologicals SA , The Government of the United States, as represen- ted by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
发明人： PAU, Maria Grazia , GOUDSMIT, Jaap , COHEN, Joseph D., GlaxoSmithKline , DUBOIS, Patrice M., GlaxoSmithKline , STEWART, V. Ann , HEPPNER, Donald
IPC分类号： A61K39/015
CPC分类号： A61K39/015 , A61K2039/5256 , A61K2039/55572 , A61K2039/55577 , A61K2039/6075 , Y02A50/412
摘要： Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.

34. 发明公开

EP2331119A1 MALARIA VACCINE 审中-公开
标题翻译：疟疾疫苗
公开(公告)号：EP2331119A1
公开(公告)日：2011-06-15
申请号：EP09816548.3
申请日：2009-07-22
申请人： The Johns Hopkins University , The Government of The United States, as Represented by The Secretary of The Army
发明人： KUMAR, Nirbhay , ANGOV, Evelina
IPC分类号： A61K39/015 , A61P33/06 , C12N15/64 , C12N5/10
CPC分类号： A61K39/015 , A61K2039/505 , A61K2039/55505 , A61K2039/55566 , C07K16/205 , C07K2317/76 , Y02A50/412
摘要： The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of development in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention.

35. 发明公开

EP2313108A2 MALARIA VACCINE OF SELF-ASSEMBLING POLYPEPTIDE NANOPARTICLES 审中-公开
标题翻译：疟疾疫苗从自组织纳米多肽
公开(公告)号：EP2313108A2
公开(公告)日：2011-04-27
申请号：EP09774269.6
申请日：2009-06-29
申请人： United States Army As Represented By The Secretary Of The Army , Lanar, David , Burkhard, Peter
发明人： LANAR, David , BURKHARD, Peter
IPC分类号： A61K39/38 , A61K39/015
CPC分类号： A61K39/015 , A61K39/385 , A61K2039/5258 , A61K2039/6031 , A61K2039/64 , Y02A50/412
摘要： The invention is directed to functionalized self-assembling polypeptide nanoparticles, and to methods of using these nanoparticles to vaccinate against malaria. The functionalized SAPN comprises a self-assembling core, and at least one epitope fused to the self-assembling core. The self-assembling core comprises a pentameric coiled-coil domain, a trimeric coiled-coil domain, and a linker. The linker joins the pentameric coiled-coil domain and the trimeric coiled-coil domain. Particular sequences of the epitopes used in the vaccine are from the Plasmodium parasite.

36. 发明公开

EP2282774A1 SUB-REGION OF A PLASMODIUM PROTEIN WITH IMPROVED VACCINE POTENTIAL, AND MEDICAL USES THEREOF 有权
标题翻译：具有改进的疫苗潜力次区域PLASMODIUMPROTEINS和医疗及其用途
公开(公告)号：EP2282774A1
公开(公告)日：2011-02-16
申请号：EP09742546.6
申请日：2009-05-07
申请人： Institut Pasteur , Université de Lausanne
发明人： DRUILHE, Pierre , CORRADIN, Giampietro , JAFARSHAD, Ali , ROUSSILLHON, Christian
IPC分类号： A61K39/395 , C07K16/20 , C07K14/445 , A61P33/06
CPC分类号： C07K16/205 , A61K39/00 , A61K39/015 , C07K14/445 , C07K2317/21 , Y02A50/412
摘要： The present application relates to a sub-region of a Plasmodium protein, with improved vaccine potential, and to medical uses thereof, notably for treatment or diagnosis of malaria. The present invention notably provides unstructured or unfolded polypeptides deriving from the PFF0165c protein of P . falciparum 3D7. The polypeptides of the invention have a high antigenicity, a high immunogenicity, have a high parasite-killing activity in the ADCI assay, and are strongly associated with clinical protection against malaria, and. The present invention thereby provides a vaccine for the palliative and/or curative treatment of malaria, which is specifically intended for infants, toddlers, children under the age of 5, pregnant women.

37. 发明公开

EP2234638A1 VACCINES FOR MALARIA 审中-公开
标题翻译：疟疾疫苗
公开(公告)号：EP2234638A1
公开(公告)日：2010-10-06
申请号：EP08865243.3
申请日：2008-12-22
申请人： GlaxoSmithKline Biologicals SA
发明人： COHEN, Joseph, D. , MARCHAND, Martine
IPC分类号： A61K39/015 , C07K14/445
CPC分类号： C07K14/445 , A61K39/015 , A61K2039/5258 , A61K2039/55555 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/6075 , C07K2319/40 , C12N7/00 , C12N2730/10123 , Y02A50/412
摘要： The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, Saccharomyces cerevisiae or Pichia pastoris. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. S antigen derived from Hepatitis B virus, and characterized in that the ratio of S to CSV-S is in the range 0.1 to 1. Suitably, the ratio of S to CSV-S is in the range 0.19 to 0.30 or 0.68 to 0.80.
摘要翻译：本发明涉及一种新型蛋白质颗粒，其制备和纯化方法，其在医学中的用途，特别是用于预防疟疾感染的方法，含有颗粒或抗蛋白质颗粒的抗体的组合物/疫苗，如单克隆或多克隆抗体和使用它们，特别是在治疗中。此外，可以通过使用酵母，酿酒酵母或巴斯德毕赤酵母来制备具有特定比例的颗粒。具体涉及包含以下单体的免疫原性蛋白质颗粒：a。包含来自P.vivax的CS蛋白和乙型肝炎S抗原（CSV-S）的序列的融合蛋白，以及b。 S抗原来源于乙型肝炎病毒，并且其特征在于S与CSV-S的比率在0.1至1的范围内。合适地，S与CSV-S的比率在0.19至0.30或0.68至0.80的范围内。

38. 发明公开

EP2190470A1 VACCINES 有权
标题翻译：疫苗
公开(公告)号：EP2190470A1
公开(公告)日：2010-06-02
申请号：EP08787080.4
申请日：2008-08-11
申请人： GlaxoSmithKline Biologicals SA
发明人： BALLOU, William, Ripley , COHEN, Joseph, D
IPC分类号： A61K39/015 , A61P33/06
CPC分类号： A61K39/015 , A61K39/0017 , A61K39/05 , A61K39/08 , A61K39/099 , A61K39/102 , A61K39/116 , A61K39/12 , A61K2039/5258 , A61K2039/55 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/6075 , A61K2039/70 , C12N2730/10134 , Y02A50/412
摘要： The invention relates to use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocytic stage of malarial infection in combination with a pharmaceutically acceptable adjuvant, in the manufacture of a medicament for vaccinating infants against malaria.
摘要翻译：本发明涉及衍生自在疟疾感染的红细胞前期阶段表达的恶性疟原虫的环子孢子蛋白（CS）蛋白的抗原与药学上可接受的佐剂组合用于制备用于接种婴儿的药物的用途，疟疾。

39. 发明公开

EP2182923A1 VIROSOMES COMPRISING HEMAGGLUTININ DERIVED FROM AN INFLUENZA VIRUS PRODUCED IN A CELL LINE, COMPOSITIONS, METHODS OF MANUFACTURING, USE THEREOF 有权
标题翻译：含有HA流感病毒的病毒颗粒，在生产的细胞系组合物，方法和应用
公开(公告)号：EP2182923A1
公开(公告)日：2010-05-12
申请号：EP08759235.8
申请日：2008-06-13
申请人： Pevion Biotech AG
发明人： ZURBRIGGEN, Rinaldo , MOSER, Christian , RASI, Silvia , KAMMER, Andreas , AMACKER, Mario , WESTERFELD, Nicole
IPC分类号： A61K9/127 , A61K38/00 , A61K39/00
CPC分类号： A61K9/127 , A61K39/015 , A61K39/12 , A61K39/145 , A61K2039/5252 , A61K2039/5258 , A61K2039/55555 , C12N2760/16134
摘要： The present invention relates to virosomes comprising hemagglutinin (HA) with improved fusion activity. Preferably, the HA comprised in said virosomes was derived from influenza virus produced in a cell line. The present invention also relates to compositions and a kit comprising the virosomes according to the invention. Further, the present invention relates to uses and methods involving said virosomes, as well as to a method for preparing same.

40. 发明授权

EP1404816B1 LIGNEES D'HEPATOMES HUMAINS LEURS OBTENTION ET LEURS APPLICATIONS 有权
标题翻译：人肝癌谁的GEWI鉴定及其用途
公开(公告)号：EP1404816B1
公开(公告)日：2010-02-17
申请号：EP02764950.8
申请日：2002-07-08
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
发明人： GRIPON, Philippe , RUMIN, Sylvie , GUGUEN-GUILLOUZO, Christiane , TREPO, Christian
IPC分类号： C12N5/09 , C12N5/02 , C12N15/63 , C12Q1/68 , C12Q1/70 , C12Q1/02 , C07K16/08 , A61K39/12 , A61K35/407 , A61K35/76 , A61P31/12
CPC分类号： A61K39/292 , A61K39/015 , A61K39/12 , A61K39/29 , A61K2039/515 , C12N5/067 , C12N7/00 , C12N2500/12 , C12N2501/39 , C12N2503/00 , C12N2503/02 , C12N2510/00 , C12N2730/10134 , Y02A50/41 , Y02A50/412
摘要： The invention concerns human hepatoma cell lines, characterised in that they are capable of being naturally infected by parasites and/or viruses; said parasites can be hepatotropic or not, such as Plasmodium or parasites of the genus leishmania and express receptors of the family of Flaviviridae and Hepadnaviridae viruses, preferably HBV and HCV. The invention has diagnostic, therapeutic and prophylactic applications.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式